NCT05745740 2023-11-27
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RemeGen Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
3 trialsNCT04063462 2019-08-21
Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02535507 2015-08-28
Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
Tongji University
Phase 2 Unknown